Pharmaceutical Medicine

, Volume 24, Issue 1, pp 1–6

Pandemic Influenza — Prevention and Treatment

Past, Present and Future
Editorial

References

  1. 1.
    Beigel J. Influenza. Crit Care Med 2008; 36: 2660–6PubMedCrossRefGoogle Scholar
  2. 2.
    Zambon M. The pathogenesis of influenza in humans. Rev Med Virol 2001; 11: 227–41PubMedCrossRefGoogle Scholar
  3. 3.
    Noah J, Noah D, Matalon S. Influenza exerts continued pressure in an era of modern medicine. Am J Respir Cell Mol Biol 2009; 41: 3–8PubMedCrossRefGoogle Scholar
  4. 4.
    Patterson K. Pandemic influenza. Totowa (NJ): Rowman & Littlefield, 1986Google Scholar
  5. 5.
    Morens D, Taugenberger J, Fauci A. The persistent legacy of the 1918 influenza virus. N Engl J Med 2009; 361: 225–9PubMedCrossRefGoogle Scholar
  6. 6.
    Russell C, Jones T, Barr I, et al. The global circulation of seasonal influenza A (H3N2) viruses. Science 2008; 320: 340–6PubMedCrossRefGoogle Scholar
  7. 7.
    Hoyle F, Wickramasinghe N. Influenza: evidence against contagion [discussion paper]. J Roy Soc Med 1990; 83: 258–61PubMedGoogle Scholar
  8. 8.
    Shinya K, Ebina M, Yamada S, et al. Influenza virus receptors in the human airway. Nature 2006; 440: 435–6PubMedCrossRefGoogle Scholar
  9. 9.
    Hers J. Disturbances of the ciliated epithelium due to influenza virus. Am Rev Respir Dis 1966; 93 (3 Pt 2): 162–71PubMedGoogle Scholar
  10. 10.
    Kaiser L, Fritz R, Straus S, et al. Symptom pathogenesis during acute influenza. J Med Virol 2001; 64: 262–8PubMedCrossRefGoogle Scholar
  11. 11.
    Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 2005; 5: 718–25PubMedCrossRefGoogle Scholar
  12. 12.
    Traves S, Proud D. Viral-associated exacerbations of asthma and COPD. Curr Opin Pharmacol 2007; 7: 252–8PubMedCrossRefGoogle Scholar
  13. 13.
    Warren-Gash C, Smeeth L, Hayward A. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease; a systematic review. Lancet Infect Dis 2009; 9: 601–10PubMedCrossRefGoogle Scholar
  14. 14.
    Smith A, Thomas M, Brockman P, et al. Effect of influenza B virus infection on human performance. BMJ 1993; 306: 760–1PubMedCrossRefGoogle Scholar
  15. 15.
    Jardine D, Hurrell M, Anderson T. A bad dose of the ‘flu. Lancet 2003; 362: 1198PubMedCrossRefGoogle Scholar
  16. 16.
    Oliveira E, Marik P, Colice G. Influenza pneumonia. Chest 2001; 119: 1717–23PubMedCrossRefGoogle Scholar
  17. 17.
    White M, Doss M, Boland P, et al. Innate immunity to influenza virus: implications for future therapy. Expert Rev Clin Immunol 2008; 4: 497–514PubMedCrossRefGoogle Scholar
  18. 18.
    Oxford J. Influenza A: a threatening virus with two faces. Biologist 2002; 49: 63–7PubMedGoogle Scholar
  19. 19.
    Taugenberger J, Morens D. 1918 influenza: the mother of all pandemics. Emerg Infect Dis 2006; 12: 15–22Google Scholar
  20. 20.
    Ansart S, Pelat C, Boelle P-Y, et al. Mortality burden of the 1918–1919 influenza pandemic in Europe. Influenza Resp Viruses 2009; 3: 99–106CrossRefGoogle Scholar
  21. 21.
    Dourmashkin R. What caused the 1918–30 epidemic of encephalitis lethargica? J Roy Soc Med 1997; 90: 515–20PubMedGoogle Scholar
  22. 22.
    Mazumder B, Almond D, Park K, et al. Lingering prenatal effects of the 1918 influenza pandemic on cardiovascular disease. J Develop Origin Health Dis 2010; 1: 26–34CrossRefGoogle Scholar
  23. 23.
    Kash J, Tumpey T, Proll S, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006; 443: 578–81PubMedGoogle Scholar
  24. 24.
    Kobasa D, Jones S, Shinya K, et al. Aberrant innate immune response in lethal infection ofmacaques with the 1918 influenza virus. Nature 2007; 445: 319–23PubMedCrossRefGoogle Scholar
  25. 25.
    Rosenau M. Experiments to determine mode of spread of influenza. J Am Med Ass 1919; 73: 311–13CrossRefGoogle Scholar
  26. 26.
    Glezen W. Emerging infections: pandemic influenza. Epidemiologic Rev 1996; 18: 64–76CrossRefGoogle Scholar
  27. 27.
    Hers J, Masurel N, Mulder J. Bacteriology and histopathology of the respiratory tract and lungs in fatal Asian influenza. Lancet 1958; 2: 1141–3PubMedCrossRefGoogle Scholar
  28. 28.
    Yuen K-Y. Avian influenza in humans. J Roy Coll Phys Edinb 2005; 35: 104–6Google Scholar
  29. 29.
    Peiris J, Yu W, Leung C, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363: 617–9PubMedCrossRefGoogle Scholar
  30. 30.
    Writing committee of the second WHO consultation on clinical aspects of human infection with avian influenza A (H5N1) virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358: 261–73CrossRefGoogle Scholar
  31. 31.
    de Jong M, Simmons C, Thanh T, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nature Med 2006; 12: 1203–7PubMedCrossRefGoogle Scholar
  32. 32.
    Seo S, Hoffmann E, Webster R. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nature Med 2002; 8: 950–4PubMedCrossRefGoogle Scholar
  33. 33.
    Hayden F, Croisier A. Transmission of avian influenza viruses to and between humans. J Infect Dis 2005; 192: 1311–4PubMedCrossRefGoogle Scholar
  34. 34.
    Enserink M, Kaiser J. Virology: avian flu finds new mammal hosts. Science 2004; 305: 1385PubMedCrossRefGoogle Scholar
  35. 35.
    MacKenzie D. Animal apocalypse. New Sci 2006; 190 (2551): 39–43Google Scholar
  36. 36.
    Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004; 363: 587–93PubMedCrossRefGoogle Scholar
  37. 37.
    Tabu C, Sharif S, Okoth P, et al. Introduction and transmission of 2009 pandemic influenza A (H1N1) virus: Kenya, June–July 2009. Morbid Mortal Wkly Rep 2009; 58: 1143–6Google Scholar
  38. 38.
    Brockwell-Staats C, Webster R, Webby R. Diversity of influenza viruses in swine and the emergence of a novel human pandemic influenza. Influenza Resp Viruses 2009; 3: 207–13CrossRefGoogle Scholar
  39. 39.
    Hancock K, Veguilla V, Lu V, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361: 1945–52PubMedCrossRefGoogle Scholar
  40. 40.
    Jamieson D, Honein M, Rasmussen S, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374: 451–8PubMedCrossRefGoogle Scholar
  41. 41.
    Mauad T, Hajjar L, Callegari G, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010; 181: 72–9PubMedCrossRefGoogle Scholar
  42. 42.
    Louie J, Chen T-H, Park S, et al. Bacterial co-infections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1): United States, May–August 2009. Morbid Mortal Wkly Rep 2009; 58: 1071–4Google Scholar
  43. 43.
    Loeb L. Beating the flu: orthodox and commercial responses to influenza in Britain, 1889–1919. Social Hist Med 2005; 18: 203–24CrossRefGoogle Scholar
  44. 44.
    Snell N. The carbolic smoke ball. Int J Pharm Med 2001; 15: 195–6Google Scholar
  45. 45.
    Jefferson T, Del Mar C, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. BMJ 2009; 339: b3675PubMedCrossRefGoogle Scholar
  46. 46.
    Update on influenza A (H1N1) 2009 monovalent vaccines. Morbid Mortal Wkly Rep 2009; 58: 1100–1Google Scholar
  47. 47.
    Song J-H, Nguyen H, Cuburu N, et al. Sublingual vaccination with influenza virus protects mice against a lethal infection. Proc Nat Acad Sci U S A 2008; 105: 1644–9CrossRefGoogle Scholar
  48. 48.
    de Jong M, Sanders R. The future of influenza vaccines. BMJ 2009; 339: b4014PubMedCrossRefGoogle Scholar
  49. 49.
    Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase 1 randomised controlled trial. Lancet 2006; 368: 991–7PubMedCrossRefGoogle Scholar
  50. 50.
    van den Berg T, Lambrecht B, Marché S, et al. Influenza vaccines and vaccination strategies in birds. Comp ImmunMicrobiol Infect Dis 2008; 31: 121–65CrossRefGoogle Scholar
  51. 51.
    Snell N. New treatments for viral respiratory tract infections: opportunities and problems. J Antimicrob Chemother 2001; 47: 251–9PubMedCrossRefGoogle Scholar
  52. 52.
    Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360: 953–6PubMedCrossRefGoogle Scholar
  53. 53.
    Gulland A. Oseltamivir resistant swine flu spreads in Welsh hospital. BMJ 2009; 339: b4975PubMedCrossRefGoogle Scholar
  54. 54.
    Sidwell R, Smee D. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin Investig Drugs 2002; 11: 859–69PubMedCrossRefGoogle Scholar
  55. 55.
    Birnkrant D, Cox E. The emergency use authorisation of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361: 2204–7PubMedCrossRefGoogle Scholar
  56. 56.
    Snell N. Novel and re-emerging respiratory infections. Expert Rev Anti Infect Ther 2004; 2: 89–96CrossRefGoogle Scholar
  57. 57.
    Wong S, Yuen K-Y. Avian influenza virus infections in humans. Chest 2006; 129: 156–68PubMedCrossRefGoogle Scholar
  58. 58.
    Webster R. Wet markets: a continuing source of severe acute respiratory syndrome and influenza? Lancet 2004; 363: 234–6PubMedCrossRefGoogle Scholar
  59. 59.
    Madjid M, Casscells W. Influenza as a bioterror threat: the need for global vaccination. Expert Opin Biol Ther 2004; 4: 265–7PubMedCrossRefGoogle Scholar
  60. 60.
    Taugenberger J, Reid A, Fanning T. Capturing a killer flu virus. Sci American 2005; 292 (1): 48–57Google Scholar
  61. 61.
    Yamada T. Poverty, wealth, and access to pandemic influenza vaccines. N Engl J Med 2009; 361: 1129–31PubMedCrossRefGoogle Scholar
  62. 62.
    Parry J. Antiviral drug in poultry is blamed for drug resistant avian flu. BMJ 2005; 331: 10PubMedCrossRefGoogle Scholar
  63. 63.
    Godlee F, Clarke M. Why don’t we have all the evidence on oseltamivir? BMJ 2009; 339: b5351PubMedCrossRefGoogle Scholar
  64. 64.
    Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009; 339: b5106PubMedCrossRefGoogle Scholar
  65. 65.
    Snell N. The clinical benefits of zanamivir in influenza. Int J Pharm Med 1999; 13: 333–5Google Scholar
  66. 66.
    Jefferson T, Jones M, Doshi P, DelMar C. Possible harms of oseltamivir: a call for urgent action. Lancet 2009; 374: 1312–3PubMedCrossRefGoogle Scholar
  67. 67.
    Krug R, Aramini J. Emerging antiviral targets for influenza A virus. Trends Pharmacol Sci 2009; 30: 269–77PubMedCrossRefGoogle Scholar
  68. 68.
    Ekiert D, Bhaba G, Elsliger M-A, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324: 246–51PubMedCrossRefGoogle Scholar
  69. 69.
    Snell N. Ribavirin: current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2001; 2: 1317–24PubMedCrossRefGoogle Scholar
  70. 70.
    Nguyen J. Triple combination of amantadine, ribavirin, and oseltamivir restores in vitro activity of antiviral drugs against resistant influenza viruses [abstract no. V-537b]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sept 12–15; San Francisco (CA)Google Scholar
  71. 71.
    Fedson D. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Resp Viruses 2009; 3: 129–42CrossRefGoogle Scholar
  72. 72.
    Vandemeer M. Role of statins in preventing death among patients hospitalized with lab-confirmed influenza infections [abstract no. 706]. Infectious Diseases Society of America 47th Annual Meeting; 2009 Oct 29–Nov 1; Philadelphia (PA)Google Scholar
  73. 73.
    Maynard A, Bloor K. The economic impact of pandemic influenza. BMJ 2009; 339: b4888PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.National Heart and Lung InstituteImperial CollegeLondonUK
  2. 2.Respiratory Infection FirmRoyal Brompton HospitalLondonUK

Personalised recommendations